Trial Design

How asking better questions and leveraging site databases can expand access to more patients.

Analysis of 330,000 clinical trials calls for improved protocol design process.

Operational and patient burden considerations for self-collection of blood specimens in clinical trials

A look forward to 2021 for the clinical trials industry.

EVP and General Manager of Hū, April Lewis, discusses why the industry has seen a decline in trial participation and what Hū is doing to combat it.

Regulatory concerns remain despite industry's quick adaptation of decentralized trials.

The industry wide shift to decentralized clinical trials includes considerations for sponsors and CROs such as global availability, global technology, and data integration.

Bayesian methods bring flexibility and speed to clinical trial design and analysis, and with increased access to the necessary computational power, are transforming today’s clinical research.

Both quality personnel and the FDA have predicted some of the issues with pandemic operations, but much is still unknown on the impact these rapidly implemented pandemic processes.

Randomized controlled trials establish strict inclusion and exclusion criteria in an effort to optimize the cohort of trial participants.

Findings from a Tufts study examining the effects of COVID-19 on clinical trials.

Tips for reducing site queries and improving workflows.

With the assistance of mobile research nursing, in-home visits provide solid alternative to trial participants, especially during COVID-19.

Decentralized clinical trials (DCTs) have ignited clinical transformation while the COVID-19 pandemic has fueled their rapid expansion.

ACT's Editor-in-Chief, Lisa Henderson, assesses the sustainability of remote trials.

Jody Casey of Elligo Health Research gives insight into the issue of diversity in trials and what needs to be done to correct it.

Disa Lee Choun, Head of Innovation at UCB, discusses how they have fostered a culture of innovation, and how the investment in piloting has benefitted clinical operational implementation during the COVID-19 pandemic.

The use of virtual trials will surge in the future and could become the de facto standard for clinical studies, says a recent Pistoia Alliance poll.

Tips for reducing site queries and improving workflows.

A look at how real world data and real world evidence are shaping more decentralized trial designs for potential COVID-19 treatments.

Study offers clues for installing rapid R&D tactics post-pandemic.

Rasmus Hogreffe, former Head of Virtual Trials at LEO Innovation Lab, and current VP of Decentralized Trial Innovation at Medable, and Morten Kirkegaard, Head of Clinical Operations and Co-founder at REDO-neurosystems, discuss their experiences with decentralized trials.

A look into the future based off what we've learned about trials during the pandemic.

A look at the future of clinical trial laboratory testing amid the emerging use of new devices at the point of care.

Competency-based and other creative approaches are needed to address the battle for talent in the clinical research workforce.

Dr. Michelle Longmire, Chief Executive Officer and founder of Medable, sits down with Moe Alsumidaie to discuss how the decentralized model will transform how trials are executed for years to come.

Findings from the most recent Biopharma Confidence Index show that the pandemic has substantially influenced biopharma executives’ expectations in key areas like artificial intelligence/machine learning and real-world evidence.

Beyond technology, awareness, and access—cultural competence is key.

A look at how real world data and real world evidence are shaping more decentralized trial designs for potential COVID-19 treatments.

Rasmus Hogreffe, former Head of Virtual Trials at LEO Innovation Lab, and current VP of Decentralized Trial Innovation at Medable, and Morten Kirkegaard, Head of Clinical Operations and Co-founder at REDO-neurosystems, discuss their experiences with decentralized trials.